Development of an amperometric biosensor based on a novel conducting copolymer for detection of anti-dementia drugs

In this study, a new amperometric biosensor was developed for the detection of the anti-dementia drugs fortified with tap water. For this purpose, electrocopolymerization of 5,6-bis(octyloxy)-4,7-di(thiophen2-yl)benzo[c][1,2,5]oxadiazole(BODT) with (2-(((9H-fluoren-9-yl)methoxy)carbonylamino) acetic acid (FMOC) on graphite electrode was successfully achieved and used as an immobilization matrix. Acetylcholinesterase (AChE) and choline oxidase (ChO) enzyme couple was immobilized on copolymer coated graphite electrode via covalent binding with the help of carbodiimide chemistry. Changes in the responses of the proposed biosensor based on AChE inhibition were recorded using acetylcholine as the substrate. The bi-enzymatic biosensor based on conducting copolymer showed good linear detection range between 0.01 and 12.0 mM and a detection limit (LOD) of 0.014 mM to acetylcholine. Surface and electrochemical characterization were performed via Scanning Electron Microscopy (SEM) and cyclic voltammetry (CV) techniques. Moreover, the design biosensor system was tested for the detection of neostigmine and donepezil as pharmaceuticals in fortified tap water samples. Very low detection limits of 0.027 mu g/L donepezil and 0.559 mu g/L neostigmine were achieved. The analysis of spiked tap water proved the biosensor capability to be used. The results were found to be in good agreement with the ones determined by HPLC/DAD technique

An acetylcholinesterase biosensor based on a conducting polymer using multiwalled carbon nanotubes for amperometric detection of organophosphorous pesticides

WOS: 000343117600006A novel amperometric biosensor based on a conducting polymer using multi walled carbon nanotube modified electrode was developed for detection of organophosphorus pesticides. Acetylcholinesterase (AChE) was successfully immobilized by covalent linkage on the modified graphite electrode. Carbon nanotubes were functionalized by electrochemical treatment. A conducting polymer; poly(4-( 2,5-di(thiophen-2-yl)-1H-pyrrol-1-yl)benzenamine) (poly( SNS-NH2)) was synthesized via electropolymerization to examine its matrix properties for biomolecule immobilization. This strategy enhanced electron transfer rate at a lower potential (+100 mV vs. Ag reference) and catalyzed electrochemical oxidation of acetylthiocholine effectively. Scanning electron microscopy (SEM), X-ray photoelectron spectroscopy (XPS), contact angle measurements and electrochemical impedance spectroscopy (EIS), cyclic voltammetry (CV) techniques were used to monitor changes in surface morphologies and electrochemical characterizations. The proposed biosensor design offered a fast response time (6 s), a wide linear range (0.05 mM and 8.00 mM) and a low detection limit (0.09 mM) with a high sensitivity (24.16 mu AmM-1 cm(-2)) for acetylthiocholine. The inhibition responses of paraoxon, parathion and chlorfenvinphos on the enzymatic activity of AChE were detected. The fabricated biosensor was tested for the detection of pesticides in fortified tap water samples. The results were found to be in good agreement with the ones determined by HPLC/DAD technique. (C) 2014 Elsevier B.V. All rights reserved.German Federal Ministry of Education and Research (BMBF WTZ project) [TUR 10-003, 01DL12015]The authors acknowledge the financial support from the German Federal Ministry of Education and Research (BMBF WTZ project TUR 10-003) grant number (01DL12015)

What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?

Background and aims: Familial hypercholesterolemia (FH) is a common genetic disease of high-level cholesterol leading to premature atherosclerosis. One of the key aspects to overcome FH burden is the generation of largescale reliable data in terms of registries. This manuscript underlines the important results of nation-wide Turkish FH registries (A-HIT1 and A-HIT2)

What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?

WOS: 000445908000052PubMed ID: 30270069Background and aims: Familial hypercholesterolemia (FH) is a common genetic disease of high-level cholesterol leading to premature atherosclerosis. One of the key aspects to overcome FH burden is the generation of largescale reliable data in terms of registries. This manuscript underlines the important results of nation-wide Turkish FH registries (A-HIT1 and A-HIT2). Methods: A-HIT1 is a survey of homozygous FH patients undergoing low density lipoprotein (LDL) apheresis (LA). A-HIT2 is a registry of adult FH patients (homozygous and heterozygous) admitted to outpatient clinics. Both registries used clinical diagnosis of FH. Results: A-HIT1 evaluated 88 patients (27 +/- 11 years, 41 women) in 19 centers. All patients were receiving regular LA. There was a 7.37 +/- 7.1-year delay between diagnosis and initiation of LA. LDL-cholesterol levels reached the target only in 5 cases. Mean frequency of apheresis sessions was 19 +/- 13 days. None of the centers had a standardized approach for LA. Mean frequency of apheresis sessions was every 19 +/- 13 (7-90) days. Only 2 centers were aware of the target LDL levels. A-HIT2 enrolled 1071 FH patients (53 +/- 8 years, 606 women) from 31 outpatients clinics specialized in cardiology (27), internal medicine (1), and endocrinology (3); 96.4% were heterozygous. 459 patients were on statin treatment. LDL targets were attained in 23 patients (2.1% of the whole population, 5% receiving statin) on treatment. However, 66% of statin-receiving patients were on intense doses of statins. Awareness of FH was 9.5% in the whole patient population. Conclusions: The first nationwide FH registries revealed that FH is still undertreated even in specialized centers in Turkey. Additional effective treatment regiments are urgently needed.Turkish Society of Cardiology; Aegerion; Amyrit; AmgenAmgen; PfizerPfizer; SanofiSanofi-AventisA-HIT1 and 2 registries are sponsored by the Turkish Society of Cardiology that receives funding from a variety of sources (including unrestricted research grants from Aegerion, Amyrit, Amgen, Pfizer, and Sanofi)

Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries

© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 licenseBackground: 80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on postoperative mortality. Methods: This was a multicentre, international prospective cohort study of consecutive adult patients undergoing surgery for primary breast, colorectal, or gastric cancer requiring a skin incision done under general or neuraxial anaesthesia. The primary outcome was death or major complication within 30 days of surgery. Multilevel logistic regression determined relationships within three-level nested models of patients within hospitals and countries. Hospital-level infrastructure effects were explored with three-way mediation analyses. This study was registered with ClinicalTrials.gov, NCT03471494. Findings: Between April 1, 2018, and Jan 31, 2019, we enrolled 15 958 patients from 428 hospitals in 82 countries (high income 9106 patients, 31 countries; upper-middle income 2721 patients, 23 countries; or lower-middle income 4131 patients, 28 countries). Patients in LMICs presented with more advanced disease compared with patients in high-income countries. 30-day mortality was higher for gastric cancer in low-income or lower-middle-income countries (adjusted odds ratio 3·72, 95% CI 1·70–8·16) and for colorectal cancer in low-income or lower-middle-income countries (4·59, 2·39–8·80) and upper-middle-income countries (2·06, 1·11–3·83). No difference in 30-day mortality was seen in breast cancer. The proportion of patients who died after a major complication was greatest in low-income or lower-middle-income countries (6·15, 3·26–11·59) and upper-middle-income countries (3·89, 2·08–7·29). Postoperative death after complications was partly explained by patient factors (60%) and partly by hospital or country (40%). The absence of consistently available postoperative care facilities was associated with seven to 10 more deaths per 100 major complications in LMICs. Cancer stage alone explained little of the early variation in mortality or postoperative complications. Interpretation: Higher levels of mortality after cancer surgery in LMICs was not fully explained by later presentation of disease. The capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention. Early death after cancer surgery might be reduced by policies focusing on strengthening perioperative care systems to detect and intervene in common complications. Funding: National Institute for Health Research Global Health Research Unit

Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. Methods: A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Findings: Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Interpretation: Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. Funding: National Institute for Health and Care Research